Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?

Dr. Sprengers et al. ReplyJournal of the American Academy Child & Adolescent PsychiatryVol. 60Issue 8PreviewBefore we elaborate on postulated discrepancies between our trial and previous bumetanide in autism spectrum disorder (ASD) trials, would like to acknowledge crucial pioneering work γ-aminobutyric acid (GABA) developmental sequence by Ben-Ari colleagues. Chloride dysregulation altered GABA polarity have been implicated neurological neurodevelopmental disorders, including some forms ASD. Etiologies underlying ASD are profoundly heterogeneous, an important challenge is link optimal treatment individual patients. Indeed, animal models indicate reversed as a target some,1,2 but not all, studies.3 The aim Bumetanide Autism Medication Biomarker (BAMBI) was replicate findings develop stratification biomarkers that may help understand expected variability response. Full-Text PDF